SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark One)
[ X ]  QUARTERLY  REPORT  PURSUANT  TO  SECTION  13 OR 15(d)  OF THE  SECURITIES
EXCHANGE  ACT OF  1934  FOR  THE  QUARTERLY  PERIOD  ENDED  MARCH  31,  2003
[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

                         Commission file number 0-21271

                       SANGUI BIOTECH INTERNATIONAL, INC.
             (Exact Name of Registrant as Specified in its Charter)

             COLORADO                                     84-1330732
  (State or other jurisdiction of                      (I.R.S.  Employer
   incorporation or organization)                     Identification  No.)

                            Alfred-Herrhausen-Str. 44
                                  58455 Witten
                                     Germany

               (Address of Principal Executive Offices) (Zip Code)
     Registrant's Telephone Number, Including Area Code: 011-49-2302-915-204



                                  -----------

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports)  and  (2)  has  been  subject  to such  filing
requirements for the past 90 days.
     Yes  [ X ]  No  [   ]

Indicate  the  number of shares  outstanding  of each of the  issuer's  class of
common stock, as of the latest practicable date:

Title  of  each  class  of  Common  Stock          Outstanding at May 14, 2003
-----------------------------------------          -----------------------------
  Common  Stock,  no par  value                           40,655,363


Transitional  Small  Business  Disclosure  Format
(Check  one);

Yes  [   ]  No  [ X ]



                                                                             -1-
<PAGE>

                                     INDEX


                       SANGUI BIOTECH INTERNATIONAL, INC.

                          PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

        Consolidated Balance Sheet at March 31, 2003 (Unaudited)............3

        Consolidated Statements of Operations and Comprehensive Loss
        (Unaudited) Three and Nine Months Ended March 31, 2003 and 2002.....4

        Consolidated Statements of Cash Flows (Unaudited) Nine Months
        Ended March 31, 2003 and 2002.......................................5

        Notes to Consolidated Financial Statements (Unaudited)..............6

Item 2. Management's Discussion and Analysis of Financial Condition
        and Results of Operations..........................................12

Item 3. Controls and Procedures............................................16

                           PART II. OTHER INFORMATION

Item 1. Legal Proceedings..................................................16

Item 2. Change in Securities and Use of Proceeds...........................17

Item 3. Defaults Upon Senior Securities....................................17

Item 4. Submission of Matters to a Vote of Securities Holders..............17

Item 5. Other Information..................................................17

Item 6. Exhibits and Reports on Form 8-K...................................17



                                                                             -2-
<PAGE>

                       SANGUI BIOTECH INTERNATIONAL, INC.
                           CONSOLIDATED BALANCE SHEET

                                     ASSETS
                                     ------

                                                               March 31,
                                                                 2003
                                                              (Unaudited)
                                                             -------------

Current assets
    Cash and cash equivalents                                $    132,014
    Available for sale securities                               1,715,125
    Prepaid expenses and other assets                             257,553
                                                             -------------
         Total current assets                                   2,104,692

Property and equipment-net                                        217,878

Patents and licenses-net                                           34,383

                                                             -------------
Total assets                                                 $  2,356,953
                                                             =============



              LIABILITIES AND STOCKHOLDERS' EQUITY
              ------------------------------------

Current liabilities
    Accounts payable and accrued expenses                    $    114,890
                                                             -------------

Commitments and contingencies

Stockholders' equity
    Preferred stock, no par value, 5,000,000 shares
    authorized, no shares issued and outstanding                        -
    Common stock,  no par value, 50,000,000 shares
    authorized, 40,655,363 shares issued and outstanding       18,345,491
    Additional paid-in capital                                  2,000,000
    Accumulated other comprehensive income                         38,453
    Accumulated deficit                                       (18,141,881)
                                                             -------------

    Total stockholders' equity                                  2,242,063

                                                             -------------
Total liabilities and stockholders' equity                   $  2,356,953
                                                             =============

                                                                             -3-
<PAGE>
<TABLE>

                       SANGUI BIOTECH INTERNATIONAL, INC.
          CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
<CAPTION>
                                                          For The                           For The
                                                     Three Months Ended                Nine Months Ended
                                                           March 31,                        March 31,
                                                          (Unaudited)                     (Unaudited)
                                                 ------------   ------------      ------------   ------------
                                                     2003           2002              2003           2002
                                                 ------------   ------------      ------------   ------------
<S>                                             <C>           <C>               <C>             <C>

Revenues                                         $         -    $         -       $         -    $         -

Operating expenses:
Research and development                             307,852        305,462           712,181        841,653
General and administrative                           262,153        178,043           778,843      1,018,801
Depreciation and amortization                        129,935         38,445           221,432        108,444
Compensation expense related to stock options             -         250,000                 -        750,000
Amortization of prepaid consulting fees                   -         110,000                 -        330,000
                                                 ------------   ------------      ------------   ------------

Total operating expenses                             699,940        881,950         1,712,456      3,048,898

Other income:
Interest income                                       14,423          6,495            53,859         66,591
Other income                                          23,235         11,878            99,347         77,169
                                                 ------------   ------------      ------------   ------------
Total other income                                    37,658         18,373           153,206        143,760

Loss from continuing operations                     (662,282)      (863,577)       (1,559,250)    (2,905,138)

Loss from discontinued operations                          -       (180,290)         (138,997)      (483,813)

                                                 ------------   ------------      ------------   ------------
Net loss                                            (662,282)    (1,043,867)       (1,698,247)    (3,388,951)

Other comprehensive income (loss):
Foreign currency translation adjustments             113,370        (59,063)          (41,261)       130,236
Unrealized (loss) gain on marketable securities       (2,264)        30,835           (83,228)       177,332
                                                 ------------   ------------      ------------   ------------

Comprehensive loss                               $  (551,176)   $(1,072,095)      $(1,822,736)   $(3,081,383)
                                                 ============   ============      ============   ============

Net loss available to common
shareholder per common share:
Net loss from continuing operations              $     (0.02)   $     (0.02)      $     (0.04)   $     (0.07)
                                                 ============   ============      ============   ============
Net loss from discontinued operations            $         -    $     (0.01)      $     (0.00)   $     (0.01)
                                                 ============   ============      ============   ============
Net loss                                         $     (0.02)   $     (0.03)      $     (0.04)   $     (0.08)
                                                 ============   ============      ============   ============

Basic and diluted weighted average
number of common shares outstanding               40,655,363     40,514,363        40,655,363     40,514,363
                                                 ============   ============      ============   ============

</TABLE>
                                                                             -4-
<PAGE>
<TABLE>

                       SANGUI BIOTECH INTERNATIONAL, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
<CAPTION>

                                                                        For The
                                                                   Nine Months Ended
                                                                       March 31
                                                                     (Unaudited)
                                                           --------------    --------------
                                                                2003               2002
                                                           --------------    --------------
<S>                                                       <C>              <C>

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss                                                   $  (1,698,247)    $  (3,388,951)
Adjustments to reconcile net loss to net cash
  used in operating activities:
      Depreciation and amortization                              221,432           127,179
      Realized gains on marketable securities                    (53,495)                -
      Realized gain on sale of assets of
        discontinued operations                                  (16,980)                -
      Loss on impairment of assets                               106,927                 -
      Compensation expense related to stock options                    -           750,000
      Amortization of prepaid consulting fees                          -           330,000
Changes in operating assets and liabilities:
      Accounts receivable                                         84,919            35,123
      Grant receivable                                           214,321                 -
      Inventories                                                 16,362           (19,067)
      Prepaid expenses and other assets                          116,819            43,321
      Accounts payable and accrued expenses                     (452,341)          (11,163)
                                                           --------------    --------------

Net cash used in operating activities                         (1,460,283)       (2,133,558)
                                                           --------------    --------------

CASH FLOWS FROM INVESTING ACTIVITIES:

      Increase in marketable securities                       (1,846,531)       (4,485,182)
      Maturities of marketable securities                      2,660,870         5,144,498
      Payment on note receivable                                  20,000                 -
      Purchase of property and equipment                         (32,911)          (45,272)
                                                           --------------    --------------

Net cash provided by investing activities                        801,428           614,044
                                                           --------------    --------------


Effect of exchange rate changes                                  (41,261)          130,236
                                                           --------------    --------------

Net decrease in cash and cash equivalents                       (700,116)       (1,389,278)

Cash and cash equivalents, beginning of period                   832,130         2,354,584
                                                           --------------    --------------

Cash and cash equivalents, ending of period                $     132,014     $     965,306
                                                           ==============    ==============


Supplemental disclosures:
      Cash paid during the period for:
      Interest                                             $           -     $           -
                                                           ==============    ==============
      Income taxes                                         $         800     $         800
                                                           ==============    ==============
</TABLE>

During  the nine  months  ended  March 31,  2003,  the  Company  recorded a note
receivable  for $60,000 from the sale of inventory and equipment  related to its
discontinued operations, which is recorded in prepaid expenses and other assets.

                                                                             -5-
<PAGE>



                       SANGUI BIOTECH INTERNATIONAL, INC.
             Notes to Consolidated Financial Statements (Unaudited)


NOTE 1 - BASIS OF PRESENTATION
------------------------------

The accompanying  consolidated  financial  statements have been prepared without
audit in accordance with accounting  principles generally accepted in the United
States of America for interim financial information and with the instructions to
Form 10-QSB and Item 301 of Regulation  S-B.  Certain  information  and footnote
disclosures  normally  included in financial  statements  prepared in accordance
with accounting  principles  generally  accepted in the United States of America
have been  condensed  or omitted  pursuant  to such rules and  regulations.  The
unaudited consolidated financial statements and notes should, therefore, be read
in conjunction with the consolidated  financial  statements and notes thereto in
the  Company's  Form 10-KSB for the year ended June 30, 2002.  In the opinion of
management,  all  adjustments  (consisting of normal and recurring  adjustments)
considered necessary for a fair presentation, have been included. The results of
operations  for the three and nine month  periods  ended  March 31, 2003 are not
necessarily  indicative  of the results that may be expected for the full fiscal
year ending June 30, 2003.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
---------------------------------------------------

Nature of Business
------------------

Sangui BioTech  International,  Inc.,  incorporated in Colorado in 1995, and its
subsidiaries  (collectively,  the "Company")  have been engaged in the research,
development, manufacture, and sales of medical products.

The operations of Sangui BioTech, Inc. ("Sangui USA"), a wholly owned subsidiary
of the  Company,  were  discontinued  during  2002 upon the sale of its in vitro
immunodiagnostics business and the subsequent merger of Sangui USA with and into
the parent company,  Sangui BioTech International,  Inc., effective December 31,
2002 (see Note 5). The merger of the two German  subsidiaries  SanguiBioTech  AG
("Sangui AG") and  GlukoMediTech AG ("Gluko AG) has been signed and submitted to
the court for  registration.  Registration  is likely to occur during the fourth
quarter of fiscal 2003.

After completion of this merger, Sangui AG will be engaged in the development of
artificial  oxygen  carriers   (external   applications  of  hemoglobin,   blood
substitute and blood additives) as well as in the development of glucose implant
sensors.

Sangui  Singapore,  incorporated in Singapore in 1999, was a regional office for
the Company that carried out research and  development  projects in  conjunction
with Sangui AG and Gluko AG. The Company  decided to discontinue  the operations
of Sangui Singapore in August 2002 (see Note 5). The Singapore office was closed
effective December 31, 2002.

Consolidation
-------------

The  consolidated  financial  statements  include the accounts of Sangui BioTech
International,   Inc.  and  its  wholly  owned  subsidiaries.   All  significant
intercompany  accounts and transactions  have been eliminated in  consolidation.
Certain  amounts in the three and nine  months  ended  March 31,  2002 have been
reclassified  to  conform  to the three and nine  months  ended  March 31,  2003
presentation.  These reclassifications have no effect on previously reported net
loss.

Use of Estimates
----------------

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States of America requires  management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosure of contingent  assets and liabilities at the date of
the  financial  statements  and the  reported  amounts of revenues  and expenses
during the respective  reporting period.  Actual results could differ from those

                                                                             -6-
<PAGE>

estimates.  Significant  estimates  made by management  are,  among others,  the
realization  of  receivables,  long-lived  assets,  and  valuation  allowance on
deferred tax assets.

Risk and Uncertainties
----------------------

The Company's line of future pharmaceutical products (artificial oxygen carriers
or blood  substitute  and  additives) and in vivo  biosensors  (glucose  implant
sensor)  being  developed  by Sangui  AG,  are  deemed  as  medical  devices  or
biologics,  and as such are governed by the Federal Food and Drug and  Cosmetics
Act and by the  regulations  of state  agencies and various  foreign  government
agencies.  The  pharmaceutical  and biosensor  products,  under  development  in
Germany, will be subject to more stringent regulatory requirements, because they
are in vivo  products  for  humans.  The Company  and its  subsidiaries  have no
experience  in  obtaining  regulatory  clearance  on these  types  of  products.
Therefore,  the Company  will be subject to the risks of delays in  obtaining or
failing to obtain regulatory clearance.

The Company's  management  believes,  based on its current  operating  plan, its
current cash and highly liquid marketable securities totaling approximately $1.8
million at March 31, 2003, are  sufficient to fund the Company's  operations and
working  capital  requirements  at least  through March 31, 2004.  However,  the
Company will need substantial additional funding to fulfil its business plan and
the Company  intends to explore  financing  sources  for its future  development
activities. No assurance can be given that these efforts will be successful.

Foreign Currency Translation
----------------------------

Assets and liabilities of the Company's  foreign  operations are translated into
U.S.  dollars  at  period-end  exchange  rates.  Net  exchange  gains or  losses
resulting from such  translation  are excluded from net loss but are included in
comprehensive   income  (loss)  and  accumulated  in  a  separate  component  of
stockholders'  equity.  Income and expenses are  translated at weighted  average
exchange rates for the period.

Cash and Cash Equivalents
-------------------------

The  Company  maintains  its cash in bank  accounts  in  Germany.  Cash and cash
equivalents  include time deposits for which the Company has no requirements for
compensating balances.

Marketable Securities
---------------------

Marketable securities are classified as available-for-sale. Unrealized gains and
losses are excluded  from net loss and are  reported as a separate  component of
other comprehensive loss in stockholders' equity.  Realized gains and losses are
included in other income and are determined based on the specific identification
of the securities bought and sold (see Note 3).

Revenue Recognition
-------------------

Revenues from product sales are recognized at the time of shipment.

Research and Development
------------------------

Research and  development  costs are charged to operations as they are incurred.
Legal fees and other direct costs incurred in obtaining and  protecting  patents
are expensed as incurred.

Stock Compensation
------------------

The Company accounts for stock-based  compensation issued to employees using the
intrinsic  value based  method as  prescribed  by  Accounting  Principles  Board
Opinion No. 25,  "Accounting  for Stock  Issued to  Employees"  ("APB  25"),  as
amended. Under the intrinsic value based method,  compensation is the excess, if
any, of the fair value of the stock at the grant date or other  measurement date
over the amount an employee must pay to acquire the stock. Compensation, if any,
is recognized over the applicable  service period,  which is usually the vesting
period. The Financial  Accounting  Standards Board ("FASB") has issued Statement
of Financial  Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based
Compensation." This standard, if fully adopted, changes the method of accounting

                                                                             -7-
<PAGE>

for all  stock-based  compensation  to the fair value  based  method.  For stock
options and  warrants,  fair value is determined  using an option  pricing model
that takes into account the stock price at the grant date,  the exercise  price,
the  expected  life of the option or warrant  and the annual  rate of  quarterly
dividends.  Compensation  expense,  if any, is  recognized  over the  applicable
service period, which is usually the vesting period.

The  adoption of the  accounting  methodology  of SFAS No. 123 for  employees is
optional  and the Company has elected to  continue  accounting  for  stock-based
compensation  issued to employees using APB 25; however,  pro forma disclosures,
as if the Company adopted the cost recognition  requirements under SFAS No. 123,
are required to be presented (see Note 4).

In December  2002,  SFAS No. 148,  "Accounting  for  Stock-Based  Compensation -
Transition  and  Disclosure",  was  issued.  SFAS No. 148 amends SFAS No. 123 to
provide  alternative  methods of transition  for a voluntary  change to the fair
value based method of  accounting  for  stock-based  employee  compensation.  In
addition,  SFAS No. 148 amends the  disclosure  requirements  of SFAS No. 123 to
require prominent  disclosures in both annual and interim  financial  statements
about the method of accounting for  stock-based  employee  compensation  and the
effect of the method used on reported  results.  The  provisions of SFAS No. 148
are effective for financial  statements  for fiscal years ending after  December
15, 2002.

The effect on net loss and loss per share if the  Company  had  applied the fair
value   recognition   provisions  of  SFAS  No.  123  to  stock-based   employee
compensation  is immaterial  for the three and nine months ended March 31, 2002.
There is no stock-based  employee  compensation expense under APB25 or pro forma
adjustment  under SFAS No.  123 for the three and nine  months  ended  March 31,
2003,  as the Company did not issue any  stock-based  compensation  to employees
since June 30, 2002 (see Note 4).

Basic and Diluted Earnings (Loss) Per Common Share
--------------------------------------------------

Basic earnings (loss) per common share is computed based on the weighted average
number of shares  outstanding for the period.  Diluted earnings (loss) per share
is  computed  by  dividing  net income  (loss) by the  weighted  average  shares
outstanding  assuming all dilutive potential common shares were issued (at March
31, 2003, there were no potential common shares).

Comprehensive Income (Loss)
---------------------------

Total  comprehensive  income (loss)  represents the net change in  stockholders'
equity during a period from sources other than  transactions  with  stockholders
and as such,  includes net earnings.  For the Company,  the  components of other
comprehensive  income (loss) are the changes in the cumulative  foreign currency
translation  adjustments  and  unrealized  gains  (losses) on securities and are
recorded as components of stockholders' equity.

Segments of an Enterprise and Related Information
-------------------------------------------------

The Company applies SFAS No. 131,  "Disclosures  about Segments of an Enterprise
and Related Information".  SFAS No. 131 establishes standards for the way public
companies  report  information  about segments of their business in their annual
financial statements and requires them to report selected segment information in
their quarterly  reports issued to  shareholders.  It also requires  entity-wide
disclosures  about the products and  services an entity  provides,  the material
countries in which it holds assets and reports  revenues and its major customers
(see Note 7).

New Accounting Pronouncements
-----------------------------

In August 2001, the FASB issued SFAS No. 144,  "Accounting for the Impairment or
Disposal of Long-Lived Assets".  SFAS No. 144 addresses financial accounting and
reporting for the impairment of long-lived  assets and for long-lived  assets to
be disposed  of. The  provisions  of SFAS No. 144 are  effective  for  financial
statements  issued for fiscal years  beginning  after  December  15,  2001,  and
interim periods within these fiscal years, with early adoption  encouraged.  The
adoption  of SFAS  No.  144 did not  have a  material  effect  on the  Company's
financial statements.

In April 2002, the FASB issued SFAS No. 145,  "Rescission of FASB No. 4, 44, and
64, Amendment of FASB Statement No. 13, and Technical  Corrections",  to update,
clarify  and  simplify  existing  accounting  pronouncements.  SFAS No. 4, which

                                                                             -8-
<PAGE>

required all gains and losses from debt  extinguishment to be aggregated and, if
material,  classified as an extraordinary  item, net of related tax effect,  was
rescinded.  Consequently,  SFAS No. 64, which  amended SFAS No. 4, was rescinded
because it was no longer necessary.  The Company does not expect SFAS No. 145 to
have a material effect on its financial statements.

In June 2002,  the FASB issued SFAS No. 146,  "Accounting  for Costs  Associated
with Exit or Disposal  Activities".  SFAS 146 addresses accounting and reporting
for costs  associated  with exit or disposal  activities and nullifies  Emerging
Issues Task Force Issue No. 94-3,  "Liability  Recognition for Certain  Employee
Termination  Benefits  and Other  Costs to Exit an Activity  (Including  Certain
Costs Incurred in a Restructuring)".  SFAS No. 146 requires that a liability for
a cost associated  with an exit or disposal  activity be recognized and measured
initially  at fair  value  when the  liability  is  incurred.  SFAS  No.  146 is
effective for exit or disposal  activities that are initiated after December 31,
2002, with early  application  encouraged.  The adoption of SFAS No. 146 did not
have a material effect on the Company's financial statements.


NOTE 3 - AVAILABLE FOR SALE SECURITIES

Available for sale securities consist of the following at March 31, 2003:


                                           Cost     Fair market   Unrealized
                                                       value      Gain (Loss)

Corporate bonds due within one year     $1,607,994   $1,504,223   $(103,771)
Corporate bonds due within five years      190,359      210,902      20,543
                                        ----------   ----------   ----------
                                        $1,798,353   $1,715,125   $ (83,228)
                                        ==========   ==========   ==========


NOTE 4 - COMPENSATION EXPENSE RELATED TO STOCK OPTIONS

Per APB No.  25,  "Accounting  for  Stock  Issued  to  Employees",  the  Company
recognized  compensation  expense for previously issued options in the amount of
$250,000 and $750,000 in the accompanying statements of operations for the three
and nine months ended March 31,  2002,  respectively.  Effective  June 30, 2002,
these  options were  cancelled by mutual  agreement  between the Company and the
option holder. As a result, no compensation expense related to stock options was
recorded for the three and nine months ended March 31, 2003.  Also,  the Company
did not issue any stock-based  compensation to employees or non-employees  since
June 30, 2002.

NOTE 5 - DISCONTINUED OPERATIONS

Sangui USA manufactured in vitro immunodiagnostic blood test kits that have been
primarily  sold  in the  United  States  and  Europe.  The  Company  decided  to
discontinue the in vitro immunodiagnostics  business in August 2002, sold Sangui
USA's  inventory and property and  equipment to an unrelated  party for $60,000,
and  closed  the  facility.  The sale  resulted  in a gain of  $16,980  which is
included  as part of  loss  from  discontinued  operations  in the  accompanying
statements of operations for the nine months ended March 31, 2003. In July 2002,
the Company received $100,000 as part of an agreement to cease manufacturing and
selling  certain  blood test kits which is  included  in loss from  discontinued
operations in the  accompanying  statements  of  operations  for the nine months
ended March 31, 2003.  The Company  decided to  discontinue  the  operations  of
Sangui  Singapore in August 2002,  recorded an  impairment  loss on property and
equipment of $106,927, and closed the facility effective December 31, 2002.

                                                                             -9-
<PAGE>


Components of amounts  reflected in the accompanying  income  statements for the
three months ended March 31, 2003 and 2002 are presented below:

<TABLE>
<CAPTION>
                                        2003                                2002
                         ----------------------------------  ----------------------------------
                           Sangui      Sangui                  Sangui      Sangui
                             USA     Singapore     Total        USA      Singapore     Total
                         ----------  ----------  ----------  ----------  ----------  ----------
<S>                     <C>         <C>         <C>         <C>        <C>         <C>

Sales                    $       -   $       -   $       -   $ 143,262   $       -   $ 143,262
Cost of sales                    -           -           -      92,629           -      92,629
Operating expenses               -           -           -     184,282      46,641     230,923
                         ----------  ----------  ----------  ----------  ----------  ----------
Loss from
 discontinued
 operations              $       -   $       -   $       -   $(133,649)  $ (46,641)  $(180,290)
                         ==========  ==========  ==========  ==========  ==========  ==========

</TABLE>

Components of amounts  reflected in the accompanying  income  statements for the
nine months ended March 31, 2003 and 2002 are presented below:

<TABLE>
<CAPTION>
                                        2003                                 2002
                         ----------------------------------  ----------------------------------
                            Sangui    Sangui                   Sangui      Sangui
                             USA     Singapore     Total        USA      Singapore     Total
                         ----------  ----------  ----------  ----------  ----------  ----------
<S>                    <C>          <C>        <C>          <C>        <C>         <C>
Sales                    $ 138,542   $       -   $ 138,542   $ 385,515   $       -   $ 385,515
Cost of sales               94,747           -      94,747     263,048           -     263,048
Operating expenses          88,564     107,644     196,208     433,050     173,230     606,280
                         ----------  ----------  ----------  ----------  ----------  ----------

Loss from operations       (44,769)   (107,644)   (152,413)   (310,583)   (173,230)   (483,813)
Other income               116,980       3,363     120,343           -           -           -
Impairment of assets             -    (106,927)   (106,927)          -           -           -
                         ----------  ----------  ----------  ----------  ----------  ----------
Income (loss) from
 discontinued
 operations              $  72,211   $(211,208)  $(138,997)  $(310,583)  $(173,230)  $(483,813)
                         ==========  ==========  ==========  ==========  ==========  ==========

</TABLE>

NOTE 6 - LITIGATION RELATED TO THE OPERATING BUSINESS

The Company may, from time to time, be involved in various litigation  resulting
from the ordinary course of operating its business.  Management is currently not
able to predict the outcome of any such cases. However, management believes that
the amount of ultimate liability,  if any, with respect to such actions will not
have a  material  effect on the  Company's  financial  position  or  results  of
operations.

                                                                            -10-

<PAGE>


NOTE 7 - BUSINESS SEGMENTS

<TABLE>
<CAPTION>
The Company reports it business segments based on geographic regions, which are as follows:

                                      Three months ended March 31,     Nine months ended March 31,
                                      -----------------------------   -----------------------------
                                            2003          2002              2003           2002
                                      -------------   -------------   -------------   -------------
<S>                                 <C>              <C>             <C>             <C>
Net sales:
Sangui USA                            $          -    $          -    $    138,542    $    385,515
Sangui BioTech International, Inc.               -               -               -               -
Sangui BioTech AG                                -               -               -               -
GlukoMediTech, AG                                -               -               -               -
Sangui BioTech PTE Ltd, Singapore                -               -               -               -
                                      -----------------------------   -----------------------------
                                      $          -    $          -    $    138,542    $    385,515
                                      =============================   =============================


Net income (loss):
Sangui USA                            $          -    $   (133,649)   $     72,211    $   (310,583)
Sangui BioTech International, Inc.          (8,037)       (372,977)       (117,663)   $ (1,487,802)
Sangui BioTech AG                         (412,454)       (281,547)       (879,492)       (796,582)
GlukoMediTech, AG                         (241,791)       (209,053)       (562,095)       (620,754)
Sangui BioTech PTE Ltd, Singapore                -         (46,641)       (211,208)       (173,230)
                                      -----------------------------   -----------------------------
                                      $   (662,282)   $ (1,043,867)   $ (1,698,247)   $ (3,388,951)
                                      =============================   =============================


Depreciation and amortization
Sangui USA                            $          -    $      3,500    $          -    $     10,690
Sangui BioTech International, Inc.               -               -               -               -
Sangui BioTech AG                          117,423          28,278         184,520          78,385
GlukoMediTech, AG                           12,512          10,167          36,912          30,059
Sangui BioTech PTE Ltd, Singapore                -           8,045               -           8,045
                                      -----------------------------   -----------------------------
                                      $    129,935    $     49,990    $    221,432    $    127,179
                                      =============================   =============================

Identifiable assets
Sangui USA                            $          -
Sangui BioTech International, Inc.          40,000
Sangui BioTech AG                          567,250
GlukoMediTech,AG                         1,749,703
Sangui BioTech PTE Ltd, Singapore                -
                                      -------------
                                      $  2,356,953
                                      =============
</TABLE>
                                                                            -11-
<PAGE>



ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
--------------------------------------------------------------------------------
OF OPERATIONS
-------------

Forward-looking Statements
--------------------------

The following  discussion  of our financial  condition and results of operations
should be read in conjunction with the consolidated financial statements and the
related notes thereto included  elsewhere in this quarterly report.  Some of the
information  in  this  quarterly  report  contains  forward-looking  statements,
including statements related to anticipated operating results,  margins, growth,
financial resources,  capital requirements,  adequacy of the Company's financial
resources,  trends in spending on research and  development,  the development of
new markets, the development,  regulatory approval,  manufacture,  distribution,
and  commercial  acceptance  of new  products,  and future  product  development
efforts.  Investors are cautioned that forward-looking  statements involve risks
and  uncertainties,  which may affect our business and prospects,  including but
not limited  to, the  Company's  expected  need for  additional  funding and the
uncertainty of receiving the additional funding,  changes in economic and market
conditions,  acceptance  of our  products by the health  care and  reimbursement
communities,   new   development   of  competitive   products  and   treatments,
administrative and regulatory approval and related  considerations,  health care
legislation and regulation,  and other factors discussed in our filings with the
Securities and Exchange Commission.

GENERAL
-------

The  Company is  primarily  involved in the  development  of  artificial  oxygen
carriers and glucose sensors.

The Company's  development projects are primarily in the preliminary stages. The
Company  is  diligently   developing   several   applications  for  its  primary
development projects, but does not anticipate beginning any government protocols
or clinical trials in the near term.

In 2002, the Board of Directors  analyzed progress and outlook for all units and
current projects within the group and assessed the key cost factors. In order to
improve the  probability of successful  market entry for its key projects in the
hemoglobin area, the Board initiated a comprehensive refocusing program aimed at
cost reduction and fast market entry.

Group Structure
---------------

In the pursuit of this program,  the Company has begun to reduce the  complexity
of the group structure by closing the Singapore  subsidiary,  merging Sangui USA
with the parent company Sangui  BioTech  International,  Inc. and initiating the
merger of the two German  subsidiaries,  GlukoMediTech AG and  SanguiBioTech AG,
into  SanguiBioTech  AG. The Company  should  benefit from the clearer  focus of
management  attention  and the  decrease in  consolidation  efforts.  Management
expects to save  approximately  50% of the group's total accounting and auditing
expenses, which, in fiscal 2002, amounted to more than $180,000.

Sangui Singapore's operations used to encompass mainly a test laboratory serving
the  purpose  of  carrying  out  experiments  on  animals.  The  closing  of the
operations in Singapore is expected to result in annual savings of approximately
$200,000 as the net loss of Sangui BioTech PTE Ltd. was  approximately  $220,000
and  approximately  $183,000  for the  years  ended  June  30,  2002  and  2001,
respectively.

After having sold the immunodiagnostic  test kit business to Axis/Shield ASA and
Biomerica,  Inc. in the first quarter of fiscal year 2003,  Sangui USA no longer
had any significant  operations  within the group.  Sangui USA,  therefore,  was
merged with the parent  company at the end of the second  quarter of fiscal year
2003. In accordance with the Company's goals and plan of  restructuring,  Sangui
Singapore  and  Sangui  USA are  presented  as  discontinued  operations  in the
accompanying consolidated financial statements.

In the course of the merger of the two German  subsidiaries  it was  resolved to
reduce further expenditures in the blood substitute,  blood additive and glucose
sensor  projects  to the  amount  necessary  to find  financing,  industrial  or
distribution  partners for further  development  and  marketing of the resulting
products.

                                                                            -12-
<PAGE>

Cost Savings
------------

As will be  discussed  below,  the  ongoing  cost-cutting  exercise  has already
contributed to reducing the operating  expenditures  of the Company.  Management
has  begun to  implement  more  efficient  processes  and  shift to  alternative
suppliers and materials  offering  better  price-performance  ratios.  Remaining
staff has been shifted to work on the most promising projects,  in particular on
the external  applications  of oxygen  carriers,  while  expenses for  long-term
development  projects have been reduced.  With regard to the long-term projects,
management focuses on identifying strategic industry and financing partners. All
costly  external  projects and orders have been  terminated  or delayed.  In the
course  of this  process,  the  number of  employees  was  reduced  by 57% to 13
fulltime  employees  at March  31,  2003  from 30  employees  at June 30,  2002.
Contracts  with 6  employees  are due to expire at the  beginning  of the fourth
quarter of fiscal 2003.

On the other hand,  consulting and legal fees related to the restructuring  have
resulted in non-recurring  expenses of approximately $ 224,000 in the first nine
months of fiscal 2003.  Management believes,  that additional  opportunities for
significant cost savings will be identified.  Special attention is being paid to
the pending lawsuits (see below). Management has requested its attorneys to take
the steps necessary to dismiss the liability claim.

In total, management has been able to reduce the Company's operating expenses by
43% to  approximately  $1.7  million  in the first nine  months of fiscal  2003,
compared to approximately  $3.0 million in the respective  period of last fiscal
year. This is partially due to the  elimination of amortization  expense related
to prepaid  consulting  fees which were written off at June 30, 2002, and to the
cancellation  of  stock  options  at  the  end  of  fiscal  2002.  Research  and
development  expenses and general and administrative  expenses have been reduced
by 15 % and 24 %,  respectively,  in the first  nine  months  of fiscal  2003 as
compared  to the  respective  period of last  fiscal  year.  This effort is also
reflected in the net cash used in operating  activities  which  decreased 30% to
approximately  $1.5  million  from  last  year's   approximately  $2.1  million.
Management,  therefore,  assumes that the current planning is realistic and that
the Company's  funds and liquidity are  sufficient to finance its  activities at
least through the period ending March 31, 2004.

FINANCIAL POSITION
------------------

The Company's  current assets decreased  approximately $2 million,  or 48%, from
June 30, 2002 to  approximately  $2.1 million at March 31, 2003. The decrease is
primarily   attributable  to  a  decrease  in  cash  and  cash   equivalents  of
approximately   $700,000,  a  decrease  in  available  for  sale  securities  of
approximately   $844,000,  a  decrease  in  grant  receivable  of  approximately
$214,000,  a decrease in accounts  receivable of  approximately  $85,000,  and a
decrease in inventories of approximately  $52,000. The decrease in cash and cash
equivalents and available for sale securities results primarily from funding the
current year's operations of the Company with little or no revenues in the three
and nine month periods ended March 31, 2003.

The Company's net property and equipment decreased  approximately  $292,000,  or
57%,  from  June 30,  2002 to  approximately  $218,000  at March 31,  2003.  The
decrease is primarily  attributable to the Company's  write-off of approximately
$107,000  of  leasehold  improvements  at  Sangui  Singapore  and  current  year
depreciation of approximately $221,000.

The Company funded its operations  primarily through its existing cash reserves.
The Company's  stockholders'  equity decreased  approximately $1.8 million.  The
primary  decrease  is  caused  by the  Company's  current  period  net  loss  of
approximately  $1.7 million,  and a decrease in accumulated other  comprehensive
income of approximately $125,000 due to foreign currency translation adjustments
and unrealized losses on marketable securities.

                                                                            -13-
<PAGE>

RESULTS OF OPERATIONS
---------------------

Three Months Ended March 31, 2003 and 2002:

Sangui AG
---------
RESEARCH AND  DEVELOPMENT.  Research and development  expenses  decreased 17% to
approximately $135,000 in 2003 from approximately $162,000 in 2002. The decrease
is due to the refocusing of research and development activities.

GENERAL AND ADMINISTRATIVE. General and administrative expenses increased 76% to
approximately  $181,000  in 2003  from  approximately  $103,000  in  2002.  This
increase is mainly  attributed to legal costs  incurred for the execution of the
ongoing refocusing program.

DEPRECIATION. Depreciation increased 318% to approximately $117,000 in 2003 from
approximately $28,000 in 2002. This increase is mainly attributed to the ongoing
restructuring of the German subsidiaries.

Gluko AG
--------
RESEARCH AND  DEVELOPMENT.  Research and development  expenses  increased 21% to
approximately $173,000 in 2003 from approximately $143,000 in 2002. The increase
is due to  compensation  and payoffs in the course of the refocusing of research
and development activities.

GENERAL AND ADMINISTRATIVE. General and administrative expenses increased 22% to
approximately  $72,000 in 2003 from approximately $59,000 in 2002. This increase
is mainly  attributed  to legal costs  incurred for the execution of the ongoing
refocusing program.

Sangui BioTech International, Inc.
---------------------------------
GENERAL  AND   ADMINISTRATIVE.   General  and   administrative   expenses   were
approximately $9,000 in 2003 and approximately $16,000 in 2002.

COMPENSATION  EXPENSE RELATED TO STOCK OPTIONS.  Compensation expense related to
stock options was $250,000 in 2002,  which  represented the  amortization of the
fair value of stock  options  previously  issued to the chairman of the Company.
Effective  June  30,  2002,  these  options  were  cancelled  and  there  is  no
compensation  expense  related to stock  options in the three months ended March
31, 2003.

AMORTIZATION OF PREPAID CONSULTING FEES. Amortization of prepaid consulting fees
was  $110,000 in 2002.  At June 30,  2002,  management  determined  that no more
benefit  would be  received  in  relation  to the  prepaid  consulting  fees and
accordingly the unamortized  balance was written off in fiscal 2002. Thus, there
was no amortization in the three months ended March 31, 2003.

Consolidated
------------
NET  LOSS.  As a result  of the above  factors  and the loss  from  discontinued
operations (see Note 5), the Company's  consolidated net loss was  approximately
$662,000,  or $0.02 per common  share,  in 2003,  compared to  approximately  $1
million, or $0.03 per common share, in 2002.

RESULTS OF OPERATIONS
---------------------

Nine months Ended March 31, 2003 and 2002:

Sangui AG
---------
RESEARCH AND  DEVELOPMENT.  Research and development  expenses  decreased 25% to
approximately $304,000 in 2003 from approximately $407,000 in 2002. The decrease
is due to the refocusing of research and development activities.

GENERAL AND ADMINISTRATIVE. General and administrative expenses increased 17% to
approximately  $460,000  in 2003  from  approximately  $393,000  in  2002.  This
increase is mainly attributed to the ongoing refocusing program.

DEPRECIATION. Depreciation increased 137% to approximately $185,000 in 2003 from
approximately $78,000 in 2002. This increase is mainly attributed to the ongoing
restructuring of the German subsidiaries.

                                                                            -14-
<PAGE>

Gluko AG
--------
RESEARCH AND  DEVELOPMENT.  Research and  development  expenses  decreased 6% to
approximately $408,000 in 2003 from approximately $432,000 in 2002. The decrease
is due to the refocusing of research and development activities.

GENERAL AND ADMINISTRATIVE.  General and administrative expenses decreased 3% to
approximately  $195,000  in 2003  from  approximately  $201,000  in  2002.  This
decrease is mainly attributed to the ongoing refocusing program.

Sangui BioTech International, Inc.
----------------------------------
GENERAL AND ADMINISTRATIVE. General and administrative expenses decreased 71% to
approximately  $124,000  in 2003  from  approximately  $425,000  in  2002.  This
decrease is related to legal costs  incurred in 2002 by the Company in a lawsuit
against a former  director of the Company  and a decrease  in  professional  and
consulting fees.

COMPENSATION  EXPENSE RELATED TO STOCK OPTIONS.  Compensation expense related to
stock options was $750,000 in 2002,  which  represented the  amortization of the
fair value of stock  options  previously  issued to the chairman of the Company.
Effective  June  30,  2002,  these  options  were  cancelled  and  there  is  no
compensation expense related to stock options in the nine months ended March 31,
2003.

AMORTIZATION OF PREPAID CONSULTING FEES. Amortization of prepaid consulting fees
was  $330,000 in 2002.  At June 30,  2002,  management  determined  that no more
benefit  would be  received  in  relation  to the  prepaid  consulting  fees and
accordingly the unamortized  balance was written off in fiscal 2002. Thus, there
was no amortization in the nine months ended March 31, 2003.

Consolidated
------------
NET  LOSS.  As a result  of the above  factors  and the loss  from  discontinued
operations (see Note 5), the Company's  consolidated net loss was  approximately
$1.7 million, or $0.04 per common share, in 2003, compared to approximately $3.4
million, or $0.08 per common share, in 2002.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

For the nine months ended March 31, 2003, net cash used in operating  activities
decreased to approximately  $1.5 million from  approximately $2.1 million in the
corresponding  period in 2002,  primarily related to a decrease in the Company's
consolidated net loss as a result of the ongoing refocusing program.

For the nine  months  ended  March 31,  2003,  net cash  provided  by  investing
activities  increased to approximately  $801,000 from approximately  $614,000 in
the corresponding  period in 2002. The principal  increase in cash is due to the
maturity of  marketable  securities  and  decrease in  purchases  of  marketable
securities.

Working capital was approximately  $2.0 million at March 31, 2003, a decrease of
approximately $1.5 million from June 30, 2002 due primarily to the Company's net
loss for the nine month  period.  A substantial  portion of the Company's  total
assets consists of cash and highly liquid  marketable  securities  classified as
available for sale securities. The highly liquid nature of these assets provides
the Company with  flexibility  in financing and managing its  business.  For the
nine-months  ended March 31, 2003,  realized  gains on the Company's  marketable
securities  were   approximately   $54,000,   and  unrealized  net  losses  were
approximately $83,000.

At March 31,  2003,  the Company had cash and liquid  marketable  securities  of
approximately $1.8 million. The Company believes that its available cash will be
sufficient to satisfy its  requirements at least through the period ending March
31, 2004.  However,  the Company  will need  substantial  additional  funding to
fulfil its business plan and the Company  intends to explore  financing  sources
for its future  development  activities.  No  assurance  can be given that these
efforts will be successful.

                                                                            -15-
<PAGE>


ITEM 3 - CONTROLS AND PROCEDURES
--------------------------------

As of March 31, 2003, an evaluation was performed under the supervision and with
the  participation of the Company's  management,  including the CEO/CFO,  of the
effectiveness of the design and operation of the Company's  disclosure  controls
and procedures.  Based on that evaluation,  the Company's management,  including
CEO/CFO,  concluded that the Company's  disclosure  controls and procedures were
effective as of March 31, 2003.  There have been no  significant  changes in the
Company's internal controls or in other factors that could significantly  affect
internal controls subsequent to March 31, 2003.

ITEM 4 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
-------------------------------------------------------------------

The  Company  has no  derivative  financial  instruments.  Exposure  to  foreign
currency exchange rates is limited,  as the Company has no operating business or
staff outside Germany since December 31, 2002.


PART II - OTHER INFORMATION
---------------------------

ITEM 1 - LEGAL PROCEEDINGS
--------------------------

On July 26,  2002,  the Company  filed a lawsuit in the United  States  District
Court for the  District of Colorado  against  Helmut  Kappes,  a director of the
Company.  In the  lawsuit,  the Company  alleges  that Mr.  Kappes is engaged in
conduct  related to the Company's  affairs that is  fraudulent,  dishonest and a
gross abuse of his  authority or  discretion  as a director and that his removal
from the  Company's  Board of  Directors  would be in the best  interest  of the
Company.  The  Company  seeks  the  permanent  removal  of Mr.  Kappes  from the
Company's  Board  of  Directors,  an  injunction  against  Mr.  Kappes  and  his
affiliates from exchanging the Company's shares for shares of an entity in which
Mr.  Kappes has a financial  interest,  compensatory  damages in an amount to be
determined  and costs of the  action.  In October  2002,  the Court  granted the
motion of counsel to Mr. Kappes to withdraw from  representation  of Mr. Kappes.
Upon consideration by the Board of Directors of the legal costs to prosecute the
claims  against Mr.  Kappes and the  likelihood  of being able to collect on any
obtained  judgment,  the company has  requested  its attorneys to take the steps
necessary to dismiss the liability claim.

In September 2002, Mr. Kappes' wife, Kerstin Kappes, and Petra Schwabe-Kutscher,
the  wife of Axel  Kutscher,  who is a former  director  of the  Company  and an
associate of Mr. Kappes, commenced an action in the United States District Court
for the District of Colorado  against the Company and its  attorneys for alleged
wrongful  refusal  to permit  Mrs.  Kappes and Mrs.  Kutscher  to  transfer  the
Company's stock. In November 2002, the Company finalized a settlement  agreement
with Mr. and Mrs. Kappes and Mrs. Kutscher  providing for the permitted transfer
by them of their Company stock under certain  conditions.  No money will be paid
by the Company in  connection  with the  settlement.  The legal  action has been
dismissed.

On August 10, 2002,  Sieglinde  Borchert,  a former director of Sangui BioTechAG
and Gluko  Meditech  AG,  filed a lawsuit  against  the two German  Corporations
alleging that she is still member of the Board of Management of these Companies.
The parties  agreed on a settlement in January  2003,  which was approved by the
Court. The legal action has been dismissed.

In December 2000, Axis/Shields ASA, a Norway corporation (Axis), filed a lawsuit
against Sangui USA alleging that Sangui USA's Carbohydrate-Deficient Transferrin
("CDT") test kit, which is used to detect chronic alcohol abuse,  constituted an
infringement  of patent  rights owned by Axis.  In March 2001, a settlement  was
reached and Sangui USA agreed to cease manufacture and sale of the CDT test kit.
Sangui USA subsequently designed a new test kit, which was then manufactured and
sold. In December 2001,  Axis filed another  lawsuit in the U.S.  District Court
for the Central District of California  against Sangui USA alleging that the new
test kit also  infringed  on Axis'  patent  rights.  Sangui  USA filed an answer
denying the claims of Axis and  counterclaimed  against  Axis for a  declaratory
judgment  of  invalidity  of the  patent of Axis and for  antitrust  violations.
Because of the  substantial  funds required to defend itself against the lawsuit
filed by Axis,  despite of a high  probability of not being found infringing the
patent held by Axis,  the Company  decided to offer its CDT business for sale to
Axis. In July, 2002, an agreement was entered into between Axis and the Company,
according  to which the  Company  agreed to cease to sell CDT kits  among  other
intangible  information for  consideration of U.S.  $100,000 paid by Axis to the
Company. As a result of this settlement,  Axis caused a dismissal with prejudice
of all its claims,  and the Company  caused a dismissal  with  prejudice  of the
Company's counterclaim. In summary, this lawsuit from Axis has been resolved.

                                                                            -16-
<PAGE>

ITEM 2 - CHANGE IN SECURITIES AND USE OF PROCEEDS
-------------------------------------------------

None

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES
----------------------------------------

Not applicable

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS
--------------------------------------------------------------

Not applicable

ITEM 5 - OTHER INFORMATION
--------------------------

As of October 29, 2002, Edgar Fritschi, VM.D., has resigned from his position as
a Director of Sangui BioTech International, Inc. and from all other positions he
previously held in the Company.

As of February 28,  2003,  Oswald  Burkhard,  M.D.,  PhD. has resigned  from his
position as a Director of Sangui BioTech International, Inc.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K
-----------------------------------------

99.1  Certification of Chief Executive Officer/Chief Financial Officer  pursuant
      to 18  U.S.C. Section  1350, as  Adopted  Pursuant  to  Section 906 of the
      Sarbanes-Oxley Act of 2002.


SIGNATURES
----------

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

SANGUI BIOTECH INTERNATIONAL, INC.


By:      /s/ Wolfgang Barnikol
         ----------------------------
         Wolfgang Barnikol
         President, Chief Executive Officer and
         Chief Financial Officer

Date:    May 14, 2003


                                                                            -17-
<PAGE>

                               CERTIFICATION UNDER
                  SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly  Report of Sangui BioTech  International,  Inc.
(the  "Company")  on Form 10-QSB for the period ended March 31,  2003,  as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
the  undersigned  certifies,  pursuant  to 18 U.S.C.  Section  1350,  as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, that:

         1. I have  reviewed  this  quarterly  report  on Form  10-QSB of Sangui
Biotech International, Inc. (the "Company");

         2. Based on my knowledge,  this  quarterly  report does not contain any
untrue  statement of a material fact or omit to state a material fact  necessary
to make the  statements  made,  in  light  of  circumstances  under  which  such
statements  were made, not misleading with respect to the period covered by this
quarterly report;

         3. Based on my knowledge, the financial statements, and other financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
Company as of, and for, the periods presented in this quarterly report;

         4. The Company's  other  certifying  officers and I are responsible for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the Company and have:

                  a) designed such disclosure  controls and procedures to ensure
that material  information  relating to the Company,  including its consolidated
subsidiaries, is made known to us by others within those entities,  particularly
during the period in which this quarterly report is being prepared;

                  b) evaluated the  effectiveness  of the  Company's  disclosure
controls and  procedures as of a date within 90 days prior to the filing date of
this quarterly report (the "Evaluation Date"); and

                  c) presented in this quarterly  report our  conclusions  about
the  effectiveness  of the  disclosure  controls  and  procedures  based  on our
evaluation as of the Evaluation Date;

         5. The Company's other certifying officers and I have disclosed,  based
on our most recent evaluation, to the Company's auditors and the audit committee
of  Company's   board  of  directors  (or  persons   performing  the  equivalent
functions):

                  a) all significant  deficiencies in the design or operation of
internal  controls which could adversely affect the Company's ability to record,
process,  summarize  and  report  financial  data  and have  identified  for the
Company's auditors any material weaknesses in internal controls; and

                  b)  any  fraud,   whether  or  not  material,   that  involves
management  or other  employees  who have a  significant  role in the  Company's
internal controls; and

         6. The Company's other certifying officers and I have indicated in this
quarterly report whether there were significant  changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent  evaluation,  including any corrective  actions with
regard to significant deficiencies and material weaknesses.



Date:    May 14, 2003                   By:  /s/ Wolfgang. Barnikol
                                             -----------------------------
                                             Wolfgang Barnikol, Chief Executive
                                             Officer and Chief Financial Officer

                                                                            -18-
<PAGE>

Exhibit 99.1

                CERTIFICATION PURSUANT TO 18 U.S.C.SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly  Report of Sangui BioTech  International,  Inc.
(the  "Company")  on Form 10-QSB for the period ended March 31,  2003,  as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
the  undersigned  certifies,  pursuant  to 18 U.S.C.  Section  1350,  as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the  requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2)The  information  contained in the Report  fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.


Date:    May 14, 2003                     /s/ Wolfgang Barnikol
                                          --------------------------------
                                          Wolfgang Barnikol
                                          President, Chief Executive Officer and
                                          Chief Financial Officer


                                                                            -19-